Last reviewed · How we verify
Adjuvant trastuzumab — Competitive Intelligence Brief
phase 2
Monoclonal antibody
Live · refreshed every 30 min
Target snapshot
Adjuvant trastuzumab (adjuvant-trastuzumab) — Pfizer Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Adjuvant trastuzumab TARGET | adjuvant-trastuzumab | Pfizer Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Adjuvant trastuzumab CI watch — RSS
- Adjuvant trastuzumab CI watch — Atom
- Adjuvant trastuzumab CI watch — JSON
- Adjuvant trastuzumab alone — RSS
Cite this brief
Drug Landscape (2026). Adjuvant trastuzumab — Competitive Intelligence Brief. https://druglandscape.com/ci/adjuvant-trastuzumab. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing